China · Delayed Price · Currency is CNY Kexing Biopharm Statistics
Total Valuation
Kexing Biopharm has a market cap or net worth of CNY 9.27 billion. The enterprise value is 9.95 billion.
| Market Cap | 9.27B |
| Enterprise Value | 9.95B |
Important Dates
The next estimated earnings date is Saturday, August 23, 2025.
| Earnings Date | Aug 23, 2025 |
| Ex-Dividend Date | Jun 12, 2025 |
Share Statistics
Kexing Biopharm has 199.38 million shares outstanding. The number of shares has increased by 1.92% in one year.
| Current Share Class | 199.38M |
| Shares Outstanding | 199.38M |
| Shares Change (YoY) | +1.92% |
| Shares Change (QoQ) | -7.17% |
| Owned by Insiders (%) | 61.15% |
| Owned by Institutions (%) | 12.32% |
| Float | 77.46M |
Valuation Ratios
The trailing PE ratio is 204.87 and the forward PE ratio is 84.51.
| PE Ratio | 204.87 |
| Forward PE | 84.51 |
| PS Ratio | 6.62 |
| PB Ratio | 5.56 |
| P/TBV Ratio | 6.41 |
| P/FCF Ratio | 125.54 |
| P/OCF Ratio | 66.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 46.30, with an EV/FCF ratio of 134.73.
| EV / Earnings | 222.71 |
| EV / Sales | 7.10 |
| EV / EBITDA | 46.30 |
| EV / EBIT | 88.40 |
| EV / FCF | 134.73 |
Financial Position
The company has a current ratio of 1.50, with a Debt / Equity ratio of 0.75.
| Current Ratio | 1.50 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 5.82 |
| Debt / FCF | 16.95 |
| Interest Coverage | 2.49 |
Financial Efficiency
Return on equity (ROE) is 2.46% and return on invested capital (ROIC) is 2.45%.
| Return on Equity (ROE) | 2.46% |
| Return on Assets (ROA) | 2.25% |
| Return on Invested Capital (ROIC) | 2.45% |
| Return on Capital Employed (ROCE) | 4.87% |
| Revenue Per Employee | 1.48M |
| Profits Per Employee | 47,154 |
| Employee Count | 947 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 3.02 |
Taxes
In the past 12 months, Kexing Biopharm has paid 32.34 million in taxes.
| Income Tax | 32.34M |
| Effective Tax Rate | 44.45% |
Stock Price Statistics
The stock price has increased by +185.82% in the last 52 weeks. The beta is 0.90, so Kexing Biopharm's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | +185.82% |
| 50-Day Moving Average | 48.07 |
| 200-Day Moving Average | 29.55 |
| Relative Strength Index (RSI) | 46.52 |
| Average Volume (20 Days) | 9,595,822 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kexing Biopharm had revenue of CNY 1.40 billion and earned 44.65 million in profits. Earnings per share was 0.23.
| Revenue | 1.40B |
| Gross Profit | 940.73M |
| Operating Income | 112.50M |
| Pretax Income | 72.75M |
| Net Income | 44.65M |
| EBITDA | 201.83M |
| EBIT | 112.50M |
| Earnings Per Share (EPS) | 0.23 |
Balance Sheet
The company has 576.27 million in cash and 1.25 billion in debt, giving a net cash position of -674.62 million or -3.38 per share.
| Cash & Cash Equivalents | 576.27M |
| Total Debt | 1.25B |
| Net Cash | -674.62M |
| Net Cash Per Share | -3.38 |
| Equity (Book Value) | 1.67B |
| Book Value Per Share | 8.42 |
| Working Capital | 441.68M |
Cash Flow
In the last 12 months, operating cash flow was 138.34 million and capital expenditures -64.52 million, giving a free cash flow of 73.82 million.
| Operating Cash Flow | 138.34M |
| Capital Expenditures | -64.52M |
| Free Cash Flow | 73.82M |
| FCF Per Share | 0.37 |
Margins
Gross margin is 67.20%, with operating and profit margins of 8.04% and 3.19%.
| Gross Margin | 67.20% |
| Operating Margin | 8.04% |
| Pretax Margin | 5.20% |
| Profit Margin | 3.19% |
| EBITDA Margin | 14.42% |
| EBIT Margin | 8.04% |
| FCF Margin | 5.27% |
Dividends & Yields
This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 0.17%.
| Dividend Per Share | 0.08 |
| Dividend Yield | 0.17% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 96.22% |
| Buyback Yield | -1.92% |
| Shareholder Yield | -1.75% |
| Earnings Yield | 0.48% |
| FCF Yield | 0.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kexing Biopharm has an Altman Z-Score of 2.19 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.19 |
| Piotroski F-Score | 6 |